Documents

A list of downloadable documents created during development.

Background information

Colon cancer (adjuvant) - capecitabine and oxaliplatin: review decision - June 2011 information
Appendix A: decision paper presented to the Institute's Guidance Executive 04 July 2011 58.63 KB
Review Proposal - April 2011 information
Appendix A: provisional matrix of stakeholders 19 April 2011 63.39 KB
Appendix B: proposal paper presented to the Institute's Guidance Executive 19 April 2011 445.21 KB
Review Decision - October 2009 information
Appendix A: decision paper considered by the Institute's Guidance Executive 20 October 2009 94.23 KB
Review Proposal - August 2009 information
Appendix A: provisional matrix of stakeholders 28 August 2009 34.88 KB
Appendix B: proposal paper presented to the Institute's Guidance Executive 28 August 2009 127.75 KB

Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination)

Consultee and commentator comments on Appraisal Consultation Document

Consultee and commentator comments on Appraisal Consultation Document 27 February 2006 99.56 KB

Appraisal Consultation Document: Colon cancer (adjuvant) - capecitabine & oxaliplatin

Appraisal Consultation Document: Colon cancer (adjuvant) - capecitabine & oxaliplatin information

Overview

Overview 28 October 2005 200.78 KB

Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report

Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report 28 October 2005 2.11 MB

Response to Consultee Comments

Response to Consultee Comments 28 October 2005 43.33 KB

Consultee and commentator comment on the assessment report

Consultee and commentator comment on the assessment report
Colon Cancer Concern 28 October 2005 14.03 KB
Institute for Cancer Research 28 October 2005 14.27 KB
NHS QIS 28 October 2005 26.78 KB
Royal College of Nursing 28 October 2005 24.89 KB
Royal College of Physicians 28 October 2005 49.67 KB

Non-manufacturer submissions

Non-manufacturer submissions
British Oncology Pharmacy Association (1) 28 October 2005 45.16 KB
British Oncology Pharmacy Association (2) 28 October 2005 47.16 KB
CancerBACUP 28 October 2005 50 KB
Cancer Concern 28 October 2005 38.95 KB
Joint submission - Royal College of Physicians, the Royal College of Radiologists, the Association of Cancer Physicians and the Joint Collegiate Council for Oncology 28 October 2005 28.09 KB
Royal College of Nursing 28 October 2005 31.83 KB

Manufacturer submissions

Manufacturer submissions
Roche 28 October 2005 27.71 KB
Roche executive summary 28 October 2005 228.9 KB
Sanofi Aventis 28 October 2005 96.53 KB
Sanofi Aventis updated submission - new evidence 28 October 2005 161.16 KB
Sanofi Aventis executive summary 28 October 2005 1.74 MB

Expert written personal statements

Expert written personal statements
Craven 28 October 2005 30.9 KB
Levine 28 October 2005 17.17 KB
Marks 28 October 2005 23.2 KB
Sharma 28 October 2005 35.79 KB

Final protocol

Final protocol 23 March 2005 54.52 KB

Final scope

Final scope 27 January 2005 26.07 KB

Summary of consultee comments on the draft scope

Summary of consultee comments on the draft scope 27 January 2005 44.46 KB

Summary of consultee and commentator comments on provisional matrix

Summary of consultee and commentator comments on provisional matrix 27 January 2005 22.15 KB

Archive: draft scope

Archive: draft scope 12 November 2004 26.51 KB

Archive: provisional matrix of consultees and commentators

Archive: provisional matrix of consultees and commentators 12 November 2004 28.6 KB

Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

Background information

Appendix A: decision paper presented to the Institute's Guidance Executive 04 July 2011 58.63 KB

Appendix A: provisional matrix of stakeholders 19 April 2011 63.39 KB

Appendix B: proposal paper presented to the Institute's Guidance Executive 19 April 2011 445.21 KB

Appendix A: decision paper considered by the Institute's Guidance Executive 20 October 2009 94.23 KB

Appendix A: provisional matrix of stakeholders 28 August 2009 34.88 KB

Appendix B: proposal paper presented to the Institute's Guidance Executive 28 August 2009 127.75 KB

Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination)

Colon cancer (adjuvant) - capecitabine & oxaliplatin (final appraisal determination) 27 February 2006 129.94 KB

Consultee and commentator comments on Appraisal Consultation Document

Consultee and commentator comments on Appraisal Consultation Document 27 February 2006 99.56 KB

Appraisal Consultation Document: Colon cancer (adjuvant) - capecitabine & oxaliplatin

Overview

Overview 28 October 2005 200.78 KB

Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report

Colon cancer (adjuvant) - capecitabine and oxaliplatin: assessment report 28 October 2005 2.11 MB

Response to Consultee Comments

Response to Consultee Comments 28 October 2005 43.33 KB

Consultee and commentator comment on the assessment report

Consultee and commentator comment on the assessment report

Colon Cancer Concern 28 October 2005 14.03 KB

Institute for Cancer Research 28 October 2005 14.27 KB

NHS QIS 28 October 2005 26.78 KB

Royal College of Nursing 28 October 2005 24.89 KB

Royal College of Physicians 28 October 2005 49.67 KB

Non-manufacturer submissions

Non-manufacturer submissions

British Oncology Pharmacy Association (1) 28 October 2005 45.16 KB

British Oncology Pharmacy Association (2) 28 October 2005 47.16 KB

CancerBACUP 28 October 2005 50 KB

Cancer Concern 28 October 2005 38.95 KB

Joint submission - Royal College of Physicians, the Royal College of Radiologists, the Association of Cancer Physicians and the Joint Collegiate Council for Oncology 28 October 2005 28.09 KB

Royal College of Nursing 28 October 2005 31.83 KB

Manufacturer submissions

Manufacturer submissions

Roche 28 October 2005 27.71 KB

Roche executive summary 28 October 2005 228.9 KB

Sanofi Aventis 28 October 2005 96.53 KB

Sanofi Aventis updated submission - new evidence 28 October 2005 161.16 KB

Sanofi Aventis executive summary 28 October 2005 1.74 MB

Expert written personal statements

Expert written personal statements

Craven 28 October 2005 30.9 KB

Levine 28 October 2005 17.17 KB

Marks 28 October 2005 23.2 KB

Sharma 28 October 2005 35.79 KB

Final protocol

Final protocol 23 March 2005 54.52 KB

Final scope

Final scope 27 January 2005 26.07 KB

Summary of consultee comments on the draft scope

Summary of consultee comments on the draft scope 27 January 2005 44.46 KB

Summary of consultee and commentator comments on provisional matrix

Summary of consultee and commentator comments on provisional matrix 27 January 2005 22.15 KB

Archive: draft scope

Archive: draft scope 12 November 2004 26.51 KB

Archive: provisional matrix of consultees and commentators

Archive: provisional matrix of consultees and commentators 12 November 2004 28.6 KB